March 2015
SACF officially launches new research lab in El Monte, California.
July 2015
SACF links Taipei Medical University with Lixte Biotechnology Holdings Inc in signing Non Disclosure Agreement that aims to explore the effectiveness of anti-cancer compound LB-100 in hepatocellular carcinoma in Asian populations.
January 2016
SACF and California Cancer Institute work together in identifying and evaluating potential biomarkers related to cancer diagnosis, prognosis, and therapy.
July 2016
SACF announces new research focus in cytotoxicity studies, protein assays, and predictive simulation models to elucidate mechanisms of action and potential targets for cancer drug development.
August 2016
SACF completes 2016 Summer Student Research Internship Program. Motivated high school and college students with strong interests in research and health sciences participate in research and work activities under the supervision of staff scientists for two-month period.
January 2017
In conjunction with University of Oslo and Human Frontier Science Program, SACF pledges support for innovative, cutting edge research related to cancer medicine and open international collaborations in the spirit of science without borders.
June 2017
SACF published “Benefits and Harms of the Center for Medicare & Medicaid Services Ruling on Next Generation Sequencing” in JAMA Internal Medicine.
August 2017
SACF 2017 Summer Student Research Internship Program.
September 2017
SACF collaborates with Yale School of Medicine on a clinical report involving novel mutation in Ribonucleotide Reductase Subunit M2 in association with mitochondrial depletion syndrome.
August 2018
SACF 2018 Summer Student Research Internship Program.
October 2018
SACF publishes “FDA Guidance for Next Generation Sequencing-based Testing: Balancing Regulation and Innovation in Precision Medicine” in Nature Genomic Medicine.
March 2019
U.S. FDA grants orphan drug designation to SACF’s Compound 056 for treatment of multiple myeloma.
April 2019
SACF relocates headquarters to Covina, CA and officially opens new lab.
July 2020
SACF signs Agreement with local biotech/pharma client to utilize Acceleration Lab for drug discovery research.
November 2020
SACF signs Agreement with biotech/pharma client to utilize Acceleration Lab for immunotherapy research.
December 2020
SACF embarks on collaboration study with Atomwise Inc. to validate AI-driven predictive models on small molecular inhibitors of ribonucleotide reductase, a critical enzyme in cancer metabolism.
January 2021
SACF collaborates with Atomwise in Drug Discovery Project identified potent RR inhibitors.
July 2021
SACF expands office and lab capabilities by leasing 2nd floor of Covina Center.
September 2021
SACF published “Cybersecurity in Science and Medicine: Threats and Challenges” in Trends in Biotechnology and Molecular Carcinogenesis.
October 2021
SACF published “Kinesin family member 11 is a potential therapeutic target and is suppressed by micorRNA-30a in breast cancer” in Mol Carcinog
August 2022
SACF 2022 Summer Student Research Internship Program.
August 2023
SACF 2023 Summer Student Research Internship Program.
November 2023
SACF published “Impact of N221S Missense Mutation in Human Ribonucleotide Reductase Small Subunit B on Mitochondrial DNA Depletion Syndrome” in Nature Scientific Reports.
March 2024
SACF is cited in landmark global study by Atomwise entitled ” AI is a viable alternative to high throughput screening: a 318-target study” published in Nature Scientific Reports.
August 2024
SACF 2024 Summer Student Research Internship Program.
